ABBV-CLS-484 Evidence: Trial Results and Peer-Reviewed Publications

Hipa.ai Research · Source: PubMed & ClinicalTrials.gov / AACT · Last updated:

The clinical evidence base for ABBV-CLS-484 comprises 1 peer-reviewed publications across 1 journals, 0 pivotal-trial primary-outcome rows reported to ClinicalTrials.gov, spanning indications including Carcinoma, Non-Small-Cell Lung. Most recent publication: The PTPN2/PTPN1 inhibitor ABBV-CLS-484 unleashes potent anti-tumour immunity., Nature, 2023.

Top peer-reviewed publications

Curated set of pivotal-trial result papers and recent publications in high-tier journals.

  1. The PTPN2/PTPN1 inhibitor ABBV-CLS-484 unleashes potent anti-tumour immunity.
    Baumgartner CK, Ebrahimi-Nik H, Iracheta-Vellve A, et al. · Nature · 2023
    PubMed: PMID 37794185 · NCT04777994 · Carcinoma, Non-Small-Cell Lung

Publications by year

2023–2023: 1 publications.

2023
1

Publications by indication

Carcinoma, Non-Small-Cell Lung (1)

  • The PTPN2/PTPN1 inhibitor ABBV-CLS-484 unleashes potent anti-tumour immunity.
    Nature · 2023 · PMID 37794185 · NCT04777994

Publications by journal

  • Nature1 paper

All ABBV-CLS-484 publications (1)

2023 (1 paper)

  1. The PTPN2/PTPN1 inhibitor ABBV-CLS-484 unleashes potent anti-tumour immunity.
    Baumgartner CK, Ebrahimi-Nik H, Iracheta-Vellve A, et al. · Nature · 2023 · Derived
    PubMed: PMID 37794185 · NCT04777994 · Carcinoma, Non-Small-Cell Lung

Sources and methodology

  • Publications: ctgov.study_references (PubMed PMIDs auto-attached by ClinicalTrials.gov to each trial), reference types RESULT, DERIVED, and BACKGROUND.
  • Per-arm outcome values: ctgov.outcome_measurements joined to ctgov.design_outcomes where outcome_type = 'PRIMARY', restricted to phase PHASE3 and PHASE2/PHASE3.
  • Publication metadata (title, journal, year, authors): PubMed E-utilities efetch.fcgi
  • Data freshness: Thu, 07 May 2026 20:24:57 GMT.
This page summarizes published evidence for general reference and does not constitute medical advice. For clinical decisions, consult the linked primary publications and your healthcare provider. Data sourced from PubMed and the ClinicalTrials.gov / AACT database maintained by the Clinical Trials Transformation Initiative (CTTI).